Allied Investment Advisors LLC Grows Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Allied Investment Advisors LLC boosted its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 1.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 80,484 shares of the company’s stock after acquiring an additional 1,121 shares during the period. Merck & Co., Inc. comprises approximately 2.6% of Allied Investment Advisors LLC’s holdings, making the stock its 14th biggest holding. Allied Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $7,338,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MRK. E&G Advisors LP raised its holdings in shares of Merck & Co., Inc. by 0.7% in the second quarter. E&G Advisors LP now owns 16,378 shares of the company’s stock valued at $1,493,000 after purchasing an additional 110 shares during the last quarter. Paulson Wealth Management Inc. raised its holdings in shares of Merck & Co., Inc. by 1.9% in the first quarter. Paulson Wealth Management Inc. now owns 6,144 shares of the company’s stock valued at $504,000 after purchasing an additional 115 shares during the last quarter. Private Management Group Inc. raised its holdings in shares of Merck & Co., Inc. by 0.4% in the first quarter. Private Management Group Inc. now owns 28,832 shares of the company’s stock valued at $2,366,000 after purchasing an additional 117 shares during the last quarter. Disciplined Investments LLC raised its holdings in shares of Merck & Co., Inc. by 24.3% in the first quarter. Disciplined Investments LLC now owns 604 shares of the company’s stock valued at $50,000 after purchasing an additional 118 shares during the last quarter. Finally, Pegasus Asset Management Inc. raised its holdings in shares of Merck & Co., Inc. by 0.3% in the first quarter. Pegasus Asset Management Inc. now owns 34,987 shares of the company’s stock valued at $2,871,000 after purchasing an additional 119 shares during the last quarter. 73.33% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $84.53 on Thursday. The stock has a market capitalization of $214.14 billion, a price-to-earnings ratio of 12.94, a PEG ratio of 1.16 and a beta of 0.33. Merck & Co., Inc. has a 52-week low of $71.50 and a 52-week high of $95.72. The stock’s 50 day moving average price is $88.96 and its two-hundred day moving average price is $87.74. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.15 and a current ratio of 1.39.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its earnings results on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.20. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The company had revenue of $14.59 billion for the quarter, compared to analysts’ expectations of $13.85 billion. During the same period last year, the business earned $1.31 EPS. Merck & Co., Inc.’s quarterly revenue was up 28.0% compared to the same quarter last year. On average, equities analysts predict that Merck & Co., Inc. will post 7.33 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.27%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is currently 42.27%.

Analyst Ratings Changes

A number of brokerages recently weighed in on MRK. Cowen boosted their target price on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a report on Monday, June 27th. SVB Leerink boosted their target price on shares of Merck & Co., Inc. from $105.00 to $109.00 and gave the company an “outperform” rating in a research report on Monday, September 12th. Morgan Stanley boosted their target price on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the company an “equal weight” rating in a research report on Friday, July 29th. Mizuho assumed coverage on shares of Merck & Co., Inc. in a research report on Friday, June 24th. They issued a “buy” rating and a $100.00 target price for the company. Finally, Berenberg Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and boosted their target price for the company from $95.00 to $100.00 in a research report on Wednesday, September 14th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $98.28.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.